Delivery Order SPE2DB20D1004-SPE2DB25F1699
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $20,132.84 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injectors with a completion date of August 26, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a delivery order valued at $4,275.96 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors. This firm fixed price delivery order, which is scheduled for completion by September 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered...
- The Defense Logistics Agency awarded a delivery order valued at $7,403.76 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. This is a firm fixed-price, non-set-aside contract with a completion date of August 14, 2025, and performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a $9,408.12 delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitive, non-set-aside contract reflects firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $9,914.47 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 ml pen injections on August 5, 2025, with completion scheduled for August 6, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors with a ceiling value of $1,143.89. This competitive award, with no set-aside designation, is issued under a firm fixed-price delivery order contract type and is scheduled for completion by August 21, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $16,403.16 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed price, non-competitive delivery order is set to be completed by August 29, 2025, with performance executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $20,598.62 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Zepbound 2.5 mg/0.5 ml pen injectors. The contract is set to be completed by September 10, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order is a non-set-aside competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25F1699Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,538.71 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injectors on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical commodities to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, has established itself as a primary supplier for military and veteran healthcare systems through its extensive portfolio of competitively awarded contracts with the Defense Logistics Agency. The company's federal contract awards demonstrate capability across a broad spectrum of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. Zepbound, a GLP-1 receptor agonist indicated for weight management, represents one of the specialized medications supplied through the company's established relationship with the Defense Health Agency and DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/3/25 |